Glioblastoma Research Group
Group Leader: Dr Paul Mulholland
Consultant in Medical Oncology and Honorary Associate Professor
- Dr Diego Ottaviani
NIHR Academic Clinical Fellow & Specialist Registrar in Medical Oncology
- Dr Nick Brown
Clinical Research Fellow & Specialist Registrar in Medical Oncology
- Dr Ben Kinnersley
Senior Research Fellow - Senior Computational Biologist
Glioblastoma is the most common and aggressive primary malignant brain tumour. Due to the lack of effective treatment options, Cancer Research UK has included glioblastoma in the category of ‘cancers of substantial unmet need’. Our goal is to improve clinical outcomes for patients with glioblastoma, from pre-clinical development of novel therapies to early and later phase clinical trials.
We have set up a national programme of clinical trials for patients with glioblastoma. We have recently completed recruitment for the IPI-GLIO trial (ISRCTN84434175) which is a phase II, open label, randomized study of ipilimumab (anti-CTLA monoclonal antibody) and temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma. In June 2022 we hope to start recruitment for newly diagnosed patients to have Ipilimumab in a clinical trial - see link for further details (https://www.clinicaltrials.gov/ct2/show/NCT05074992).
Molecular mechanisms in glioblastoma
Alongside clinical trials, we are running a translational programme to improve our understanding of the molecular mechanisms driving glioblastoma response and resistance to treatment. There is emerging evidence that DNA organisation is critical in mediating responses to cancer treatment including chemotherapy and immunotherapy. We are characterising the DNA architecture in glioblastoma and how it can be modified to enhance treatment efficacy.